Larimar Therapeutics Inc. (LRMR), which is developing a drug for a rare inherited condition, has clinical data readouts expected later this year that investors should watch closely.
The company's lead drug candidate is Nomlabofusp, being developed as a potential disease-modifying therapy for Friedreich's ataxia.
Friedreich's ataxia (FA) is a rare inherited condition caused by a mutation in FXN, a gene that provides instructions for making the mitochondrial protein frataxin. Most individuals with FA produce only about 20-40% of normal frataxin (FXN) levels. This genetic disorder causes progressive damage to the nervous system, resulting in motor weakness and sensory loss. About 20,000 patients worldwide are affected by FA, including around 5,000 in the United States. The majority of the remaining cases are found in Europe. Notably, nearly 70% of patients are diagnosed before the age of 14.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.